KAPA
AMEXKairos Pharma Ltd.
$0.61+0.00 (+0.48%)
News25/Ratings0
Price$0.61-0.15 (-19.57%)
2026-01-222026-04-27
News · 26 weeks21-67%
2025-11-022026-04-26
Mix890d
- SEC Filings5(63%)
- Other3(38%)
Latest news
25 items- PRKairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare InnovationCompany selected as an Emerald honoree for Innovator of Biotech Solutions Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner of the 2026 Pinnacle Awards for Healthcare, being selected as an Emerald honoree for Innovator of Biotech Solutions for addressing cancer drug resistance. Kairos Pharma was recognized for its differentiated approach to targeting the biological mechanisms that allow tumors to evade treatment. Rather than developing standalone therapies, Kairos is advancing resistance-modulating treatments designed to restore and extend the effectiveness of existing cancer th
- SECSEC Form 424B3 filed by Kairos Pharma Ltd.424B3 - Kairos Pharma, LTD. (0001962011) (Filer)
- SECSEC Form 424B3 filed by Kairos Pharma Ltd.424B3 - Kairos Pharma, LTD. (0001962011) (Filer)
- SECSEC Form 10-K filed by Kairos Pharma Ltd.10-K - Kairos Pharma, LTD. (0001962011) (Filer)
- SECKairos Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Kairos Pharma, LTD. (0001962011) (Filer)
- PRKairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn TherapeuticsThe next‑generation, AI‑designed pan‑EGFR inhibitor for EGFR‑mutant lung cancer significantly expands the Company's oncology pipeline Targeting a $16.2 Billion Market Opportunity Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it has entered into binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment. John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: "The signing of binding terms to acquire CL‑273 represents a pivotal step in building Kairos Pharma's next generation of targeted therapies for EGFR‑mutant lung cancer. Th
- SECKairos Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Kairos Pharma, LTD. (0001962011) (Filer)
- PRKairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn TherapeuticsTransformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market. Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-sma
- SECSEC Form EFFECT filed by Kairos Pharma Ltd.EFFECT - Kairos Pharma, LTD. (0001962011) (Filer)
- NEWSDealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's EventATLANTIC CITY, NJ / ACCESS Newswire / January 23, 2026 / DealFlow Events today announced the growing list of companies scheduled to present and participate in one-on-one meetings with investors and analysts at the DealFlow Discovery Conference, taking place January 28-29, 2026, at the Borgata Hotel Casino & Spa in Atlantic City.More than 100 public and private companies are expected to participate in the conference, which brings together investors, analysts, growth company executives, and capital markets professionals for two days of company presentations, structured networking, and pre-scheduled 1:1 meetings.Below is the current list of companies confirmed to present and take meetings. Publ
- PRKairos Pharma to Present at 3rd Annual DealFlow Discovery ConferenceCSO Neil Bhowmick to deliver company presentation and will be available for investor meetings Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it will participate in the DealFlow Discovery Conference, taking place Jan. 28-29, 2026, at the Borgata Hotel in Atlantic City, NJ. Kairos Pharma Chief Scientific Officer Neil Bhowmick will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Event Details: 3rd Annual DealFlow Discovery Conference The Borgata Hotel, Casino & Spa Atlantic City, NJ Jan. 28-29, 2026 Investors interested in schedul
- INSIDERChief Scientific Officer Bhowmick Neil was granted 171,756 shares, increasing direct ownership by 15% to 1,311,739 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- INSIDERDirector Bae Hyun W. was granted 29,084 shares, increasing direct ownership by 66% to 73,370 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- PRKairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate CancerCompany recognized for advancing ENV‑105, a first‑in‑class resistance‑modulating antibody for metastatic castration‑resistant prostate cancer Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it has been selected as a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced Prostate Cancer. Kairos earned this recognition for its work advancing ENV‑105 (carotuximab), a first‑in‑class CD105‑targeting monoclonal antibody designed to modulate resistance pathways in metastatic castration‑resistant prostate cancer (mCRPC). ENV‑105 is being develop
- INSIDERVP of Research and Development Murali Ramachandran was granted 152,672 shares, increasing direct ownership by 104% to 299,529 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- INSIDERDirector Keyoung Hansoo Michael was granted 29,084 shares (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- INSIDERDirector Singhvi Rahul was granted 19,084 shares, increasing direct ownership by 63% to 49,204 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- INSIDERCEO and Chairman Yu John S was granted 190,840 shares, increasing direct ownership by 486% to 230,105 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- INSIDERChief Financial Officer Samuelson Doug was granted 152,672 shares, increasing direct ownership by 109% to 293,039 units (SEC Form 4)4 - Kairos Pharma, LTD. (0001962011) (Issuer)
- SECSEC Form 10-Q filed by Kairos Pharma Ltd.10-Q - Kairos Pharma, LTD. (0001962011) (Filer)
- PRKairos Pharma Provides Shareholder UpdateCompany makes important progress in 2025 and looks ahead into 2026 Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides an overview of key 2025 milestones and outlook into 2026 in a Letter to Shareholders from CEO John Yu, M.D. presented below. To our valued Kairos Pharma Shareholders, This year, Kairos has been focused on executing its Phase 2 randomized clinical trial of ENV105 in combination with apalutamide in patients with advanced metastatic prostate cancer. The study is designed to evaluate the safety, tolerability, and early signs of efficacy of ENV105, a CD105 antagonist, in men whose disease has progre
- PRKairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) MeetingInterim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safety data Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today presents on the positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the annual European Society Medical Oncologists meeting in Berlin, Germany. An interim efficacy analysis from the ongoing trial with ENV-105, a first-in-class CD105 antagonist, is being tested for safety and early efficacy in men with metastatic pr
- SECKairos Pharma Ltd. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Kairos Pharma, LTD. (0001962011) (Filer)
- SECKairos Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Kairos Pharma, LTD. (0001962011) (Filer)
- PRKairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cancer therapeutics, today announced that it has been selected to present at the European Society for Medical Oncology (ESMO) Congress. Kairos's presentation, titled, "Preliminary safety and clinical activity from a Phase 2 study of apalutamide and carotuximab in advanced, castration-resistant prostate cancer" will take place in Berlin, Germany on October 17–21, 2025. Prostate cancer remains one of the most diagnosed cancers in men, with over a million new cases annually in the U.S. alone. Resistance to androgen-targeted therapies represents a major clinical challenge
KAPA FAQ
5 questionsWhere does KAPA stock trade?
Kairos Pharma Ltd. (KAPA) is listed on AMEX.What sector and industry is KAPA in?
Kairos Pharma Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Kairos Pharma Ltd. go public?
Kairos Pharma Ltd. (KAPA) completed its IPO in 2024.What companies are similar to KAPA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare KAPA side-by-side with any of them on Quantisnow.How can I track KAPA on Quantisnow?
Quantisnow aggregates Kairos Pharma Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KAPA to receive live email and push alerts on every new disclosure.